ClinicalTrials.gg
Active, not recruitingNCT04793932CASSANDRAUpdated Apr 9, 2025

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)

A Phase 3 interventional study of PAXG and mFOLFIRINOX in Pancreas Ductal Adenocarcinoma, sponsored by Associazione Italiana per lo Studio del Pancreas. Active, not recruiting at 22 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Associazione Italiana per lo Studio del Pancreas · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2020, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main aim of this study is to compare the efficacy of short-course versus long-course pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.

Read the detailed description

Pancreatic cancer is the seventh cause of death in cancer patients and more than 94% of affected patients die of cancer disease. In the majority of cases, the diagnosis is done at an advanced stage and only 10-20% of patients can be treated with a surgical resection. For this neoplasia, a radical resection may be an effective treatment. Nevertheless, results obtained with surgery alone are rather inadequate, showing a median survival of 12-14 months and 2-year survival of almost 20%: it seems evident the necessity to use complementary treatments in order to improve survival rate in this group of patients.

Pancreatic cancer can relapse locally, at the level of tumoral bed, of the regional lymph nodes, on the immediately adjacent peritoneal surface or on contiguous organs. Also, distant metastases are quite frequent, mainly to the liver, at the entire peritoneal surface and, rarely, to the extra-abdominal organs. The rapid appearance of these metastases after surgical resection strongly suggests the presence of subclinical metastatic diffusion at an early phase of the disease.

Currently, combination chemotherapy based on the mFOLFIRINOX regimen is considered the therapeutic standard in the adjuvant setting, in young and fit patients. Unfortunately, mFOLFIRINOX is burdened with strong haematological and extra-haematologic toxicity and just 2/3 of patients are able to complete the treatment. Recently, PAXG regimen [(Cisplatin (P), Abraxane (A), Capecitabine (X), Gemcitabine (G)] when compared to AG in randomized studies, showed an improvement in terms of progression-free survival (PFS) and overall survival in borderline resectable, locally advanced and metastatic patients. To date, several ongoing randomized trials are investigating the efficacy of perioperative or neoadjuvant strategies in early stage PDAC. Only few studies are available regarding neoadjuvant treatment: some are outdated, numerically inconsistent, retrospective, or not randomized. In this scenario, it aims to better investigate pre-operative therapeutic strategy.

For this purpose, two randomizations are planned.

  1. FIRST RANDOMIZATION. Eligible patients will be randomized (1:1), stratifying by basal CA19.9 level (\<5 ULN vs ≥ 5ULN) and centre to receive:

    PAXG or mFOLFIRINOX for 4 months

  2. SECOND RANDOMIZATION. Patients without progression or limiting toxicity after 4 months of the assigned chemotherapy in the study, will be randomized (1:1), stratifying by treatment assigned by the first randomization, to receive 2 further months of the same chemotherapy either BEFORE or AFTER surgery.
02

Conditions studied

  • Pancreas Ductal Adenocarcinoma

Keywords

  • neoadjuvant chemotherapy
  • PAXG
  • mFOLFIRINOX
  • resectable
  • borderline resectable
03

In context

Lead sponsor

Associazione Italiana per lo Studio del Pancreas is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cyto/histological diagnosis of pancreatic ductal adenocarcinoma*;
  2. Clinical stage I-III disease according to TNM 8th Ed. 2017 [appendix 1];
  3. Resectable or borderline resectable disease, as anatomically defined according to NCCN Guidelines Version 1.2020 - Pancreatic Adenocarcinoma [appendix 2] and biologically defined according to the International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 (CA 19.9 > 500 IU/ml) (Isaji et al., 2018);
  4. Performance Status > 60% [appendix 3];
  5. Age > 18 and ≤ 75 years;
  6. Adequate bone marrow function (GB ≥ 3500/mm3, neutrophils ≥1500/mm3, ≥ 100000/mm3, ≥10 g/dl);
  7. Adequate kidney function (serum creatinine \< 1.5 mg/dL);
  8. Adequate liver function:

    • and AST \< 3
    • Serum total ≤ 1.5 ULN or in subjects with biliary stenting ≤ 2 ULN;
  9. No prior treatment (chemotherapy, radiotherapy and/or surgery) for pancreatic cancer;
  10. Women must not be on pregnancy or lactation;
  11. Patient of must agree to use two medically acceptable methods of (one for the patient and one for the partner) during the study and for a minimum of the following 6 months; this applies to patients of both sexes. [appendix 4];
  12. Patient information and signed written .

Exclusion criteria

Exclusion Criteria:

  1. Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, cystadenocarcinoma and other periampullary .
  2. Prior (within 1 year) or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin
  3. Symptomatic duodenal stenosis;
  4. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
  5. Known infection with or C, or history of (HIV) infection, or subject receiving or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications
  6. Clinical stage IV (including ascites or malignant pleural effusion) disease according to TNM 8th Ed. 2017 [appendix 1];
  7. Locally advanced disease according to NCCN Guidelines Version 1.2020 - Pancreatic Adenocarcinoma [appendix 2];
  8. Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:

    1. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)
    2. History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary pneumonitis or multiple allergies
    3. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or abnormality, cerebrovascular accident, , or seizure disorder
  9. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  10. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  11. Any condition that confounds the ability to interpret data from the study
  12. Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up;
  13. Pre-existing neuropathy
  14. c.1679GG, c.1905+1AA, c.2846TT mutations in homozygous in DPYD gene. Dose modification according to DPYD and UGT1A1 mutations are reported in Table 1 (https://www.aiom.it/wp-content/uploads/2019/10/2019_Racc-analisi-farmacogenetiche.pdf.)
  15. Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine.
  16. Concurrent treatment with other experimental drugs;
  17. Fructose intolerance.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Active comparator
    PAXG Arm A

    cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).

    Drug: PAXG

  • Active comparator
    mFOLFIRINOX Arm B

    irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).

    Drug: mFOLFIRINOX

  • Active comparator
    short-course chemotherapy

    Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy

    Drug: short-course chemotherapy

  • Active comparator
    long-course chemotherapy

    Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery

    Drug: long-course chemotherapy

Interventions

  • DrugPAXG

    Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days

  • DrugmFOLFIRINOX

    Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days

  • Drugshort-course chemotherapy

    other two months of chemotherapy after surgery

  • Druglong-course chemotherapy

    other two months of chemotherapy before surgery

06

What researchers measure

Primary outcomes

  1. Event-free survival

    to compare in terms of event free survival (EFS) the efficacy of PAXG to that of mFOLFIRINOX. EFS is defined as the time from randomization to: RECIST 1.1 progression \[At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression\]; CA19.9 failure (defined as 2 consecutive increases of serum level ≥20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.

    Time frame: 12 weeks

  2. Event-free survival

    to compare in terms of event free survival (EFS) the efficacy of 4 months pre-operative and 2 months postoperative chemotherapy to that of 6 months of pre-operative chemotherapy . EFS is defined as the time from randomization to: RECIST 1.1 progression \[At least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20 percent, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression\]; CA19.9 failure (defined as 2 consecutive increases of serum level ≥20 percent, separated by at least 4 weeks); recurrence; preoperative or intraoperative unresectability; intraoperative evidence of metastases; death for any cause; whichever occurs first. R1 resections will NOT be considered as events whereas R2 resections will be.

    Time frame: 12 weeks

Secondary outcomes

  1. Overall survival

    the time between the date of the patient's enrollment and the death of the patient for any cause or the last time the patient was seen alive

    Time frame: 36 months

  2. RECIST 1.1 radiological response

    Radiological response evaluation during the treatment by using RECIST 1.1 criteria

    Time frame: 4-6 months

  3. Ca19.9 response rate

    Biochemical response evaluation during the treatment by using this specific marker

    Time frame: 4-6 months

  4. Surgery outcome

    The evaluation of resectability rate.

    Time frame: 4-6 months after chemotherapy

  5. Surgery outcome

    The evaluation of surgical mortality and morbidity rate.

    Time frame: 4-6 months after chemotherapy

  6. Surgery outcome

    The evaluation of intra- and post-operative metastasis rate.

    Time frame: 4-6 months after chemotherapy

  7. Surgery outcome

    The evaluation of N0 and R0 resections rate.

    Time frame: 4-6 months after chemotherapy

  8. Incidence of Treatment Adverse Events

    The evaluation of drugs safety and tolerability by SAE report

    Time frame: 4-6 months

  9. Quality of life

    Impact of treatment on quality of life assessed by the latest version of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30)

    Time frame: 4-6 months

  10. Quality of life

    Impact of treatment on quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life scale for pancreatic cancer (EORTC QLQ - PAN26)

    Time frame: 4-6 months

07

Study locations

22 sites
  • Oncologia Medica e Prevenzione Oncologica Centro di riferimento oncologico (CRO), IRCCS
    Aviano, 33081, Italy
  • Oncologia Medica Az. Ospedaliera Istituto Tumori "Giovanni Paolo II"
    Bari, 70124, Italy
  • Oncologia ASST pg23
    Bergamo, 24127, Italy
  • Oncologia Medica Azienda Universitaria Ospedaliera Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • Oncologia Medica dell'Az.Ospedaliera Fondazione Poliambulanza Istituto Ospedaliero
    Brescia, 25124, Italy
  • Oncologia Medica AOU Careggi
    Florence, 50134, Italy
  • Oncologia Ospedale Generale Provinciale
    Macerata, 62100, Italy
  • Oncologia Medica dell'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, 47014, Italy
  • Oncologia dell'Istituto Clinico Humanitas
    Milan, 20089, Italy
  • IRCCS San Raffaele
    Milan, 20132, Italy
  • Oncologia Medica Falck Niguarda
    Milan, 20162, Italy
  • Oncologia Medica Az Ospedaliera AOU Cagliari Policlinico Universitario Dullio Casula
    Monserrato, 09042, Italy
  • Oncologia Medica AOU FEDERICO II
    Naples, 80131, Italy
  • Oncologia Medica 1 Ospedaliera Istituto Oncologico Veneto IRCCS
    Padova, 35128, Italy
  • Oncologia Medica Arnas Civico
    Palermo, 90121, Italy
  • Oncologia Medica 2 Az. Ospedaliera Universitaria Pisana
    Pisa, 56126, Italy
  • Oncologia Medica Az. Ospedaliera Fondazione Policlinico Universitario A. Gemelli IRCCS
    Rome, 00168, Italy
  • Chirurgia Generale e Oncologica dell'AZ. Ospedaliera Ordine Mauriziano
    Torino, 10028, Italy
  • Divisione Chirurgica Az. Ospedaliera AULSS2
    Treviso, 31100, Italy
  • SOC di Oncologia Az. Ospedaliera Sanitaria Universitaria Friuli Centrale-P.O. "S. Maria della Misericordia"
    Udine, 33100, Italy
  • Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
    Verona, 37136, Italy
  • Oncologia ULSS8 Berica
    Vicenza, 36100, Italy
08

References and documents

Publications

  • Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. PubMed 18391598 ↗
  • Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12. PubMed 22237835 ↗
  • Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016 Jul 26;115(3):290-6. doi: 10.1038/bjc.2016.209. Epub 2016 Jul 12. PubMed 27404453 ↗
  • Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4. PubMed 29625841 ↗
  • Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24. PubMed 30149366 ↗
  • Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. doi: 10.1016/S2468-1253(18)30196-1. Epub 2018 Jul 7. PubMed 30220407 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Mar 2025, 52 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2021
First posted
Mar 11, 2021
StartActual
Nov 3, 2020
Primary completionActual
Mar 15, 2025
CompletionEst.
Jan 31, 2026
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04793932
Lead sponsor
Associazione Italiana per lo Studio del Pancreas
Collaborators
High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Nov 3, 2020
Primary completion
Mar 15, 2025
Completion
Jan 31, 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Michele Reni, MD
study chair · IRCCS San Raffaele

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion